10 research outputs found
Additional file 3 of Incidental finding of elevated pulmonary arterial pressures during liver transplantation and postoperative pulmonary complications
Additional file 3: Supplementary Table S1-S3. Analysis on each individual pulmonary complications
Additional file 5 of Incidental finding of elevated pulmonary arterial pressures during liver transplantation and postoperative pulmonary complications
Additional file 5: Supplementary Table S8. Sensibility analysis of multivariable models with other mPAP cutoffs or mPAP as a continuous variable
Additional file 4 of Incidental finding of elevated pulmonary arterial pressures during liver transplantation and postoperative pulmonary complications
Additional file 4: Supplementary Tables S4. Multivariable analysis on blood loss (coefficient multiplicatif). Supplementary Tables S5. Dialysis (exclusion of patients with preoperative dialysis). Supplementary Tables S6. Graft failure. Supplementary Tables S7. Infection
Additional file 1 of Incidental finding of elevated pulmonary arterial pressures during liver transplantation and postoperative pulmonary complications
Additional file 1: Supplemental document 1. Anesthesia and surgical protocol
Additional file 2 of Incidental finding of elevated pulmonary arterial pressures during liver transplantation and postoperative pulmonary complications
Additional file 2: Supplemental document 2. Standardized definition of the primary outcome
Hematological adverse events and their management during triple therapy after liver transplantation.
<p>Abbreviations: EPO: erythropoietin; Hb: hemoglobin level; NC: neutrophil count; ns: non significant; PC: platelet count; PEG-IFN: pegylated interferon; RBV: ribavirin; W: week</p><p>Hematological adverse events and their management during triple therapy after liver transplantation.</p
Virological responses during triple therapy after liver transplantation.
<p>An early virological response (EVR) was observed when the HCV viral load was undetectable at week 12. An extended virological response meant negative HCV RNA at week 4 and week 12. An EOT (end of treatment response) was achieved when HCV RNA was undetectable at 48 weeks. SVR12 and SVR 24 were defined as undetectable HCV RNA at 12 and 24 weeks after the discontinuation of antiviral therapy, respectively. Five patients discontinued triple therapy (three with TVR and two with BOC) before week 48 with undetectable HCV RNA and still achieved an SVR12 and SVR24.</p
Mean estimated glomerular filtration rates during triple therapy.
<p>The median decrease of eGFR was 7.68mL/min with BOC and 8.53mL/min with TVR (<i>P</i> = ns). Seven patients were hospitalized because of acute kidney failure, six of whom were in the TVR group. No CNI overdoses were observed and all patients recovered after a saline infusion.</p
Description of immunosuppressive therapy management.
<p>Abbreviations: CNI: calcineurin inhibitors; IS: immunosuppression; n: number; sd: standard deviation; MMF: mycophenolate mofetil; PI: protease inhibitors</p><p>Description of immunosuppressive therapy management.</p
Baseline characteristics of the study population.
<p>Abbreviations: HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; M: male; n: number; PEG-IFN: pegylated interferon</p><p>Continuous variables are expressed as mean ± standard deviation.</p